COLLEEN VALDEZ: Open Payments
NPI 1740762384 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,419 in 77 payments from 16 companies in 2025. Trend: 2023 $968 · 2024 $1,060 · 2025 $1,419
Food & beverage: $1,320Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $320 |
| Janssen Biotech, Inc. | 7 | $209 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $138 |
| Ardelyx, Inc. | 8 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $118 |
| PFIZER INC. | 6 | $105 |
| QOL Medical, LLC | 4 | $96 |
| Gilead Sciences, Inc. | 4 | $66 |
| Madrigal Pharmaceuticals | 2 | $58 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
Products named: TREMFYA, XIFAXAN, IBSRELA, RINVOQ, ENTYVIO, Sucraid, XELJANZ, CREON.
Industry payments across AL — which companies pay providers there.
